Orthocell Ltd, a regenerative medicine company, will hold an investor webinar on October 22, 2026, to discuss its September quarter results and the US launch of its Remplir nerve repair product. The webinar will feature presentations from CEO Paul Anderson, CFO Jim Piper, and Chief Commercial Officer Adam Wood, covering financial updates and strategic priorities. This event provides investors with insights into the company’s operational progress and future plans in the US market. The webinar starts at 8:00am AWST / 11:00am AEDT and requires registration.
Orthocell's upcoming investor webinar on October 22 is noted alongside Pluang's Health-sector market snapshot as of Oct 20, 2026 05:21 WIB: out of 150 priced US health stocks, 81 rose and 67 fell today. Notable movers include SYRE at USD 84.71 (+6.02%), TWST at USD 140.34 (+5.72%) with 100% buy order activity on Pluang and a typical hold time of 27 days, and SLS at USD 10.48 (+5.01%) with a typical hold time of 5 days.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
